Management of Subclinical Hyperthyroidism

Diagnosis

The American College of Physicians recommends that laboratory values (TSH 0.32 with normal T4 0.9) are consistent with subclinical hyperthyroidism, defined as a TSH below the lower threshold of the reference interval (usually 0.4 mIU/L) with normal T4 levels 1
The Endocrine Society suggests that this patient falls into the "low but detectable" TSH category (0.1-0.4 mIU/L) rather than the more concerning "clearly low" or "undetectable" (<0.1 mIU/L) category 1
The Society for Immunotherapy of Cancer notes that subclinical hyperthyroidism is more commonly seen with anti-PD-1/PD-L1 drugs than with anti-CTLA-4 agents in patients receiving immunotherapy 2

The American Society of Clinical Oncology recommends repeat thyroid function tests in 3-6 months to confirm persistence of the abnormal TSH 3
The American College of Physicians advises that transient TSH suppression can occur due to various conditions and should be ruled out before making treatment decisions 1
The Society for Immunotherapy of Cancer suggests considering checking thyroid antibodies such as thyroid peroxidase (TPO) antibody and TSH receptor antibodies to determine etiology 2, 3

The American Heart Association recommends assessing for symptoms of hyperthyroidism such as weight loss, palpitations, heat intolerance, tremor, or anxiety 2
The American Society of Clinical Oncology advises that if symptomatic, consideration should be given to more aggressive monitoring or treatment 3
The American College of Physicians notes that if asymptomatic, observation is appropriate 3

The American College of Physicians recommends that for asymptomatic patients with TSH 0.1-0.4 mIU/L, observation without medication is the recommended approach 1, 3
The American Society of Clinical Oncology suggests continuing monitoring with thyroid function tests every 3-6 months 3
The American College of Physicians advises that if TSH decreases to <0.1 mIU/L or symptoms develop, treatment options should be reconsidered 3

The American Society of Clinical Oncology recommends that for symptomatic patients or those with TSH <0.1 mIU/L, beta-blockers (propranolol or atenolol) can be used for symptom control 3

The American Society of Clinical Oncology warns that overtreatment of subclinical hyperthyroidism, especially in the "low but detectable" TSH range, can lead to iatrogenic hypothyroidism 3
The American College of Physicians advises that failure to repeat thyroid function tests to confirm persistence before initiating treatment should be avoided 1, 3
The American College of Physicians notes that treating based on a single abnormal lab value without considering clinical context should be avoided 1

The American Society of Clinical Oncology recommends repeat thyroid function tests in 3-6 months 3
The American Society of Clinical Oncology suggests that if TSH normalizes, continue monitoring annually 3
The American Society of Clinical Oncology advises that if TSH decreases to <0.1 mIU/L or symptoms develop, consideration should be given to treatment options 3
The American College of Physicians recommends monitoring for progression to overt hyperthyroidism, which would be indicated by low TSH with elevated T4 1

In adults, especially those ≥ 60 years, a suppressed TSH (<0.1 mIU/L) with normal free T4 and free T3 (subclinical hyperthyroidism) raises the risk of atrial fibrillation by 3–5‑fold and increases cardiovascular mortality. This risk is evident even when patients are asymptomatic. 4
In individuals > 60 years whose TSH is <0.5 mIU/L, all‑cause mortality is up to 2.2‑fold higher and cardiovascular mortality up to 3‑fold higher compared with those with normal TSH. The association persists after adjustment for common confounders. 4
Failure to address suppressed TSH in elderly patients directly contributes to ongoing bone loss and heightened cardiovascular risk, underscoring the need for active management. 4

Suppressed TSH (<0.1 mIU/L) in women ≥ 65 years markedly increases the incidence of hip and spine fractures, reflecting accelerated bone mineral density loss. The effect is independent of other osteoporosis risk factors. 4

Clinicians should not consider a low TSH with normal thyroid hormones clinically insignificant; the documented cardiovascular and skeletal complications warrant evaluation and, when appropriate, treatment. 4